Quince Therapeutics (QNCX) to Release Earnings on Monday

Quince Therapeutics (NASDAQ:QNCX) is expected to be issuing its Q4 2025 results before the market opens on Monday, March 23rd. Analysts expect Quince Therapeutics to post earnings of ($0.2250) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 27, 2026 at 4:00 PM ET.

Quince Therapeutics Stock Down 8.8%

NASDAQ:QNCX opened at $0.08 on Friday. The stock’s 50 day moving average price is $0.95 and its two-hundred day moving average price is $1.87. Quince Therapeutics has a 12-month low of $0.08 and a 12-month high of $4.55. The firm has a market capitalization of $4.45 million, a price-to-earnings ratio of -0.07 and a beta of 1.28.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. cut shares of Quince Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 29th. Lucid Cap Mkts downgraded Quince Therapeutics from a “strong-buy” rating to a “strong sell” rating in a research report on Friday, January 30th. Citigroup lowered shares of Quince Therapeutics from a “market outperform” rating to a “market perform” rating in a research report on Friday, January 30th. D. Boral Capital lowered Quince Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. Finally, Citizens Jmp cut shares of Quince Therapeutics from a “market outperform” rating to a “market perform” rating in a research note on Friday, January 30th. One analyst has rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus target price of $7.67.

Hedge Funds Weigh In On Quince Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Superstring Capital Management LP purchased a new position in Quince Therapeutics in the fourth quarter worth $2,877,000. Quadrature Capital Ltd purchased a new position in shares of Quince Therapeutics in the fourth quarter worth about $268,000. Almitas Capital LLC raised its holdings in Quince Therapeutics by 88.0% during the 4th quarter. Almitas Capital LLC now owns 930,134 shares of the company’s stock valued at $3,116,000 after acquiring an additional 435,356 shares during the period. Adage Capital Partners GP L.L.C. purchased a new stake in Quince Therapeutics during the 4th quarter worth about $7,538,000. Finally, OMERS ADMINISTRATION Corp bought a new position in shares of Quince Therapeutics in the fourth quarter valued at approximately $308,000. Hedge funds and other institutional investors own 30.75% of the company’s stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.